VEGF inhibition in urothelial cancer: the past, present and future
Sanaz N. Ghafouri(University of California, Los Angeles), Alexandra Drakaki(Columbia University Irving Medical Center), Aaron Burkenroad(University of California, Los Angeles), Bara Almomani(University of California, Los Angeles), John Shen(University of California, Los Angeles), Dimitrios Stefanoudakis(APLA Health), Morgan Pantuck(Temple University)
Cited by 19
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2021|411
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
|Current Issues in Molecular Biology|2024|78